Serum platelet-derived growth factor-BB levels as a potential biomarker in assessing the metabolic activity of lesions in alveolar echinococcosis patients.

BACKGROUND

Alveolar echinococcosis (AE) is a chronic disease caused by the larval stage of Echinococcus multilocularis. Assessing the metabolic activity of AE lesions is critical to evaluate disease progression and survey treatment options. There is an urgent need to identify more rapid, convenient, and non-invasive clinical detection methods to substitute the current techniques. Herein, we evaluated the viability of platelet-derived growth factor-BB (PDGF-BB) as a biomarker for detecting the metabolic activity of AE patients and their correlations with clinicopathological features of AE patients.

METHODS

Sera were collected from 28 AE patients and a homogenous cohort of 28 healthy individuals. The concentration of serum PDGF-BB homodimers (sPDGF-BB) was assessed via an enzyme-linked immunosorbent assay (ELISA). Liver tissue samples were obtained from a consecutive series of 28 AE patients who underwent surgical resection. Thereafter, we determined the expression levels of local PDGF-BB and platelet-derived growth factor receptor-β (PDGFR-β) through immunohistochemistry (IHC). Correlations of PDGF-BB expression levels with clinicopathological features of AE patients were analyzed using SPSS.

RESULTS

The concentrations of sPDGF-BB were significantly lower in AE patients (p < 0.0001), particularly in High Metabolically Active AE patients (HMAE) patients (p < 0.05). The expression levels of PDGF-BB and its receptor were both significantly higher in close liver tissue (CLT) in AE patients (p < 0.0001). We also found that metabolically active AE and sPDGF-BB are significantly negatively correlated (r = -0.624, p = 0.0004). Beside, the local expression levels of PDGF-BB was positively correlated with metabolic activity, PNM stage, and lesion size. Notably, the sPDGF-BB levels were proposed as a potential biomarker for assessing metabolic activity of AE, with 81.0% sensitivity and 85.7% specificity (95% confidence interval, p = 0.003).

CONCLUSIONS

Serum levels of PDGF-BB could be a simple, non-invasive, and quick biomarker for assessing the metabolic activity of lesions in AE patients.